Modulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-α kinoid

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 699-703

  Assier, Eric ^a   Semerano, Luca ^a,b   Duvallet, Emilie ^a   Delavallée, Laure ^a   Bernier, Emilie ^c   Laborie, Marion ^c   Grouard Vogel, Géraldine ^c   Larcier, Patrick ^c   Bessis, Natacha ^a   Boissier, Marie Christophe ^a,b  

^a Hôpital Avicenne   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Neovacs SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE LIMPET HEMOCYANIN ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; PHOSPHATE BUFFERED SALINE; PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA KINOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, NEUTRALIZING; AUTOANTIBODIES; DRUG INCOMPATIBILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES;

EID: 84860345483     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05649-11     Document Type: Article

References (30)

1. Bachmann F, Nast A, Sterry W, Philipp S. 2010. Safety and efficacy of the tumor necrosis factor antagonists. Semin. Cutan Med. Surg. 29:35-47.
2. Bartelds GM, et al. 2010. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naïve patients: A cohort study. Ann. Rheum. Dis. 69:817-821.
3. Biton J, et al. 2011. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J. Immunol. 186:3899-3910.
4. Boissier MC. 2011. Cell and cytokine imbalances in rheumatoid arthritis. Joint Bone Spine 78:230-234.
5. Chackerian B, Lowy DR, Schiller JT. 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108:415-423. (Pubitemid 32730788)
6. Cozon G, et al. 1991. Transient secretory IgA deficiency in mice after cyclophosphamide treatment. Clin. Immunol. Immunopathol. 61:93-102.
7. Dalum I, et al. 1999. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat. Biotechnol. 17:666-669. (Pubitemid 29316144)
8. Delavallée L, et al. 2008. Vaccination with cytokines in autoimmune diseases. Ann. Med. 40:343-351. (Pubitemid 351882892)
9. Delavallée L, et al. 2008. Early and long-lasting protection from arthritis in TNF-α transgenic mice vaccinated against TNF-α. Ann. Rheum. Dis. 67:1332-1338.
10. Delavallée L, et al. 2009. Active immunization to tumor necrosis factoralpha is effective in treating chronic established inflammatory disease: A long term study in a transgenic model of arthritis. Arthritis Res. Ther. 11:R195.
11. Everly JJ, Walsh RC, Alloway RR, Woodle ES. 2009. Proteasome inhibition for antibody-mediated rejection. Curr. Opin. Organ Transplant. 14:662-666.
12. Feldmann M, Steinman L. 2005. Design of effective immunotherapy for human autoimmunity. Nature 435:612-619. (Pubitemid 40825501)
13. Flick DA, Gifford E. 1984. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods 68:167-175. (Pubitemid 14133657)
14. Furst DE. 2010. Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 28:S5-S12.
15. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. 2005. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin. Arthritis Rheum. 34:819-836. (Pubitemid 40740207)
16. Jin J, Chang Y, Wei W. 2010. Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis. Acta Pharmacol. Sin. 31:1133-1140.
17. Kapetanovic MC, et al. 2006. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45:106-111. (Pubitemid 43033885)
18. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. 2007. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 46:608-611. (Pubitemid 46523304)
19. Keffer J, et al. 1991. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10:4025-4031. (Pubitemid 21905432)
20. Le Buanec H, et al. 2006. TNF alpha kinoid vaccination-induced neutralizing antibodies to TNF alpha protects mice from autologous TNF alpha driven chronic and acute inflammation. Proc. Natl. Acad. Sci. U. S. A. 103:19442-19447. (Pubitemid 46026050)
21. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868. (Pubitemid 40446280)
22. Matthews JN, Altman DG, Campbell MJ, Royston P. 1990. Analysis of serial measurements in medical research. BMJ 300:230-235. (Pubitemid 20045528)
23. Nadkarni S, Mauri C, Ehrenstein MR. 2007. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 204:33-39. (Erratum, 204:205. (Pubitemid 46148753)
24. Notley CA, et al. 2008. Blockade of tumor necrosis factor in collageninduced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 205:2491-2497.
25. Rad FH, et al. 2007. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl. Acad. Sci. U. S. A. 104: 2837-2842. (Pubitemid 46327966)
26. Semerano L, Assier E, Delavallée L, Boissier MC. 2011. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin. Biol. Ther. 11:545-550.
27. Sfikakis PP. 2010. The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 11:180-210.
28. Tissot AC, et al. 2008. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomised, placebo-controlled phase IIa study. Lancet 371:821-827. (Pubitemid 351323893)
29. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. 2007. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J. Rheumatol. 34:952-957. (Pubitemid 46774837)
30. Waterston AM, et al. 2005. Phase I study of TNF-α AutoVaccine in patients with metastatic cancer. Cancer Immunol. Immunother. 54:848-857. (Pubitemid 40991327)